Chlorella

Chlorella vulgaris / Chlorella pyrenoidosa
Evidence Level
Limited
3 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Chlorella is a single-celled freshwater green algae packed with chlorophyll, complete protein (60% by weight), vitamins, minerals, and unique compounds including Chlorella Growth Factor (CGF). Widely paired with spirulina in greens formulas, chlorella is particularly valued for its heavy metal detoxification properties, immune modulation, and nutritional density, with a cell wall that must be cracked for bioavailability.

Studied Dose 3–10 g/day dried powder (tablets or powder); cracked cell wall preparation essential
Active Compound Chlorophyll and Chlorella Growth Factor (CGF) — cracked/broken cell wall chlorella required for bioavailability

Benefits

Heavy metal and toxin binding

Chlorella's cell wall and unique binding proteins chelate heavy metals (mercury, lead, cadmium, arsenic) and persistent organic pollutants in the GI tract and bloodstream, facilitating their excretion. Clinical studies in Japanese populations show chlorella supplementation reduces blood mercury and dioxin levels.

Immune system modulation

Chlorella Growth Factor (CGF) — a unique nucleotide/peptide complex found only in chlorella — stimulates NK cell activity, macrophage function, and interferon production. RCTs show enhanced immune response to influenza vaccination and reduced incidence of upper respiratory infections.

Lipid and blood sugar regulation

Multiple RCTs show chlorella significantly reduces total cholesterol, LDL, and triglycerides, while improving fasting blood glucose and insulin resistance markers in adults with metabolic syndrome and non-alcoholic fatty liver disease.

Nutritional density and greens support

Chlorella provides complete protein with all essential amino acids, vitamins B1, B2, B3, B6, B12, vitamin C, iron, magnesium, and zinc in bioavailable forms. As a whole-food supplement, it contributes meaningful micronutrient intake alongside its functional effects.

Liver function support in NAFLD

A 2021 systematic review and meta-analysis of 7 RCTs (8 treatment arms) found Chlorella vulgaris supplementation significantly reduced serum AST levels (WMD: -9.15 U/L, 95% CI -16.09 to -2.21) in patients with non-alcoholic fatty liver disease (NAFLD). A 2026 GRADE-assessed systematic review of 7 RCTs (375 NAFLD patients) confirmed beneficial effects on liver enzymes, lipid profile, and metabolic markers. The Panahi RCT (76 NAFLD patients, 1200 mg/day × 3 months) showed C. vulgaris adjunct therapy reduced ALT, AST, triglycerides, HbA1c, and HOMA-IR vs. metformin alone. Mechanism likely involves reduced hepatic lipid accumulation, improved insulin sensitivity, and antioxidant effects on hepatocytes. Note: most trials are conducted in Iran with relatively small samples; larger Western trials are needed to confirm generalizability.

Mechanism of action

1

Cell wall binding and chelation of heavy metals

Chlorella's cell wall contains sporopollenin-like compounds and unique binding proteins that form stable complexes with heavy metal ions (Hg2+, Pb2+, Cd2+) and organochlorine compounds. These complexes pass through the intestine without absorption and are excreted in feces, reducing systemic heavy metal burden.

2

Chlorella Growth Factor immunostimulation

CGF — a water-soluble nucleotide-peptide extract from chlorella — directly stimulates NK cell cytotoxicity, macrophage phagocytosis, and secretory IgA production. CGF also supports gut barrier function and beneficial microbiome populations, contributing to systemic immune benefits.

3

Chlorophyll and antioxidant activity

Chlorella's extremely high chlorophyll content (2–3% by dry weight — among the highest of any supplement) acts as an antioxidant, promotes alkalinity, and may bind carcinogens and heterocyclic amines from cooked meat in the GI tract, potentially reducing their systemic absorption.

Clinical trials

1
Chlorella and Mercury Reduction — RCT
PubMed

Randomized controlled trial examining Chlorella tablet supplementation effects on blood and urinary mercury, dioxin, and furan levels in adults with high fish consumption. (Uchikawa et al. 2010 or related Japanese chlorella heavy metal trials)

Adults with high fish consumption.

Chlorella supplementation reduced blood mercury and dioxin/furan levels vs placebo. Note: most evidence comes from Japanese groups studying methylmercury exposure; effects in non-fish-consuming populations are less established. Mechanism via cell wall binding of heavy metals in the GI tract.

2
Chlorella and Lipid Profiles in Metabolic Syndrome — RCT
PubMed

Randomized controlled trial of chlorella (5 g/day) vs placebo in adults with metabolic syndrome over 12 weeks. Outcomes: lipid panel, fasting glucose, insulin sensitivity. (Panahi et al. 2012, J Diet Suppl — or related metabolic syndrome trial)

Adults with metabolic syndrome. 12-week intervention.

Chlorella significantly reduced total cholesterol, LDL, triglycerides, and fasting glucose vs placebo. Improved insulin resistance index. Mechanism may involve combined fiber, peptides, and carotenoid effects. Note: small trials, multiple chlorella species used (vulgaris, pyrenoidosa) with potentially different effects.

3
Chlorella vulgaris in NAFLD — Meta-Analysis
PubMed

Systematic review and meta-analysis of 7 RCTs (8 treatment arms) evaluating Chlorella vulgaris supplementation in NAFLD patients. Outcomes: liver enzymes (AST, ALT), lipid profile, glycemic markers. (2021 meta-analysis)

Pooled across 7 NAFLD RCTs.

Significant reduction in serum AST levels (WMD: -9.15 U/L, 95% CI -16.09 to -2.21). ALT showed reduction trend but did not consistently reach significance. Suggests adjunctive role in NAFLD; not sufficient as monotherapy. Modest effect sizes.

Side effects and drug interactions

Common Potential side effects

GI discomfort (bloating, gas, loose stools) common during first week — usually resolves
Green discoloration of stools (harmless — chlorophyll)
Photosensitivity (sunburn sensitivity) reported rarely with high doses
Avoid in iodine-sensitive individuals — chlorella contains iodine

Important Drug interactions

Anticoagulants (warfarin) — chlorella contains vitamin K; monitor INR if adding chlorella supplementation
Immunosuppressants — chlorella stimulates immune function; may counteract cyclosporine or tacrolimus
Heavy metal chelation therapy — may interfere with pharmaceutical chelation timing; separate doses by several hours

Frequently asked questions about Chlorella

What is the recommended dosage of Chlorella?

The clinically studied dose for Chlorella is 3–10 g/day dried powder (tablets or powder); cracked cell wall preparation essential. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Chlorella used for?

Chlorella is studied for heavy metal and toxin binding, immune system modulation, lipid and blood sugar regulation. Chlorella's cell wall and unique binding proteins chelate heavy metals (mercury, lead, cadmium, arsenic) and persistent organic pollutants in the GI tract and bloodstream, facilitating their excretion.

Are there side effects from taking Chlorella?

Reported potential side effects may include: GI discomfort (bloating, gas, loose stools) common during first week — usually resolves Green discoloration of stools (harmless — chlorophyll) Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Chlorella interact with medications?

Known drug interactions may include: Anticoagulants (warfarin) — chlorella contains vitamin K; monitor INR if adding chlorella supplementation Immunosuppressants — chlorella stimulates immune function; may counteract cyclosporine or tacrolimus Consult a pharmacist or healthcare provider if you take prescription medications.

Is Chlorella good for antioxidant?

Yes, Chlorella is researched for Antioxidant support. A 2021 systematic review and meta-analysis of 7 RCTs (8 treatment arms) found Chlorella vulgaris supplementation significantly reduced serum AST levels (WMD: -9.15 U/L, 95% CI -16.09 to -2.21) in patients with non-alcoholic fatty liver disease (NAFLD).